3 Biotech Stocks to Buy Now

These biotech stocks could deliver outsized returns for long-term investors.

[{"selector":"#anim-b03499e6-8b19-4675-9653-1300800b9bc7 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(25.64480082703082%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}] [{"selector":"#anim-95b3d1a9-5c6b-42d2-87d4-746297f97426","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-91ddeb92-a528-4275-bb67-2ae7acf05d79","keyframes":{"transform":["translate3d(0px, -267.1824%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

VIR Vir Biotechnology $19.21

[{"selector":"#anim-8c7821b1-849d-4813-a87e-34c7fc920e53 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(25.64480082703082%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}] [{"selector":"#anim-0b8a8a39-6490-4774-8b52-8496f5409c84","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-f9a0793c-8a20-4036-92a3-eeb0a4366e97","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}]

Vir Biotechnology (VIR): While its Covid-19 treatment may no longer be a cash cow, its Hepatitis B drugs hold great potential.

[{"selector":"#anim-de1cff64-3c56-4891-9cbe-1a1d5aa328eb [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(25.64480082703082%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}] [{"selector":"#anim-fed08c0a-98dc-41b3-be5e-3d94b2934c12","keyframes":{"opacity":[0,1]},"delay":0,"duration":2000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-481acc95-b72f-4d81-b42b-0ceade4101d7","keyframes":{"transform":["translate3d(0px, -176.63744%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

EXEL Exelixis $16.90

[{"selector":"#anim-3e960039-5f00-4f32-a887-32a24b6a3eba [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(25.64480082703082%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}] [{"selector":"#anim-93c4c2d4-1162-4243-b687-3f311275c820","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-416a53c8-7ee0-4bea-bd19-ba8661150ed0","keyframes":{"transform":["translate3d(0px, -235.95876%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

Exelixis (EXEL): The firm has a massive cash base thanks to the success of its Cabozantinib franchise.

[{"selector":"#anim-524f3a84-7873-4231-a14e-7899ac999772 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(25.64480082703082%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}] [{"selector":"#anim-0a5064ce-6b67-4cff-b993-4621b0792f9a","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-0211ce46-6c4a-4c14-a03f-ca77cf6bcca6","keyframes":{"transform":["translate3d(0px, -179.94817%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

BCRX BioCryst Pharmaceuticals $13.37

[{"selector":"#anim-fef56bf2-baf0-4c08-9b3c-56de5c1151d1 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(25.64480082703082%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}] [{"selector":"#anim-f27ae04f-235f-46aa-bc28-2254d2d69542","keyframes":{"transform":["translate3d(125.09092%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(.2, 0, .8, 1)","fill":"both"}] [{"selector":"#anim-f7c7103a-0370-48db-ac20-2b614dd19c12","keyframes":{"transform":["rotateZ(180deg)","rotateZ(0deg)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(.2, 0, .5, 1)","fill":"forwards"}]

BioCryst Pharmaceuticals (BCRX): Its flagship drug, Orladeyo, has been gobbling up market share.

[{"selector":"#anim-276930e1-6616-4c2a-a83b-ee8a9bd2f576 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(25.64480082703082%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}] [{"selector":"#anim-50b74c72-1cf8-435d-8e47-3458274775b7","keyframes":[{"transform":"rotate(-540deg) scale(0.1)","opacity":0},{"transform":"none","opacity":1}],"delay":0,"duration":1000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both","iterations":1}]

Please check our stories

[{"selector":"#anim-5632c3d2-5285-4662-a9bb-9987b4f9766f [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(25.64480082703082%, 0, 0) translate(25%, 0%) scale(1.5)","translate3d(0%, 0, 0) translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.14,.34,.47,.9)","fill":"forwards"}] [{"selector":"#anim-a9c20a9c-740c-4448-9734-456a59f4afcf","keyframes":[{"transform":"rotate(-540deg) scale(0.1)","opacity":0},{"transform":"none","opacity":1}],"delay":0,"duration":1000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both","iterations":1}] Learn more

3 Biotech Stocks to Buy Now

Image credit: Google

These biotech stocks could deliver outsized returns for long-term investors.

Image credit: Google

VIR Vir Biotechnology $19.21

Image credit: Google

Vir Biotechnology (VIR): While its Covid-19 treatment may no longer be a cash cow, its Hepatitis B drugs hold great potential.

Image credit: Google

EXEL Exelixis $16.90

Image credit: Google

Exelixis (EXEL): The firm has a massive cash base thanks to the success of its Cabozantinib franchise.

Image credit: Google

BCRX BioCryst Pharmaceuticals $13.37

Image credit: Google

BioCryst Pharmaceuticals (BCRX): Its flagship drug, Orladeyo, has been gobbling up market share.

Image credit: Google

Please check our stories

Image credit: Google